Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 4/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11943270 | 0.77 | MAPT (0.48) | DCTPP1DGAT1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL11943261 | 0.75 | DCTPP1 (0.47) | DCTPP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11943315 | 0.75 | MEN1 (0.57) | ALDH1A1SMN1; SMN2KDM4EPKMNPC1 | |
| SCHEMBL11943268 | 0.74 | DCTPP1 (0.42) | DCTPP1DGAT1ALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL13304384 | 0.74 | DCTPP1 (0.46) | DCTPP1ALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL11943275 | 0.74 | FAAH (0.52) | ALDH1A1KDM4E | |
| SCHEMBL13329125 | 0.74 | FAAH (0.48) | DCTPP1SMN1; SMN2KDM4EPKMNPC1 | |
| SCHEMBL11943303 | 0.74 | ALDH1A1 (0.55) | DCTPP1ALDH1A1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL11943120 | 0.73 | DCTPP1 (0.42) | DCTPP1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11943123 | 0.73 | DCTPP1 (0.42) | DCTPP1ALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | DCTPP1 625/4885DGAT1 3046/4885ALDH1A1 2437/4885 |
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | DPM1, GMPS, MAN2A1 | DCTPP1 209/4885DGAT1 4292/4885ALDH1A1 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.